Assessment of the 31-Gene Expression Profile Test by Dermatologists: A Cross-Sectional Survey from National Dermatology Conferences

Justin W. Marson, MD¹, Graham H. Litchman, DO, MS², Ryan Svoboda, MD, MS³, Alex Glazer, MD⁴, Aaron S. Farberg, MD⁵, Richard R. Winkelmann, DO⁶, Darrell S. Rigel, MD, MS⁷, The Skin Cancer Prevention Working Group

¹National Society for Cutaneous Medicine, New York, NY
²Department of Dermatology, St. John’s Episcopal Hospital, Far Rockaway, NY
³Department of Dermatology, Penn State College of Medicine, Hershey, PA
⁴Dermatology Science and Research Foundation, Buffalo Grove, IL
⁵Section of Dermatology, Baylor University Medical Center, Dallas, TX
⁶OptumCare, Los Angeles, CA
⁷Department of Dermatology, NYU Grossman School of Medicine, New York, NY

ABSTRACT

Background: The 31-gene expression profile (31-GEP) test uses 31 genetic markers obtained from the initial biopsy of a melanoma to assess melanoma-specific survival and sentinel lymph node positivity.

Objective: To assess the professional understanding, opinions, and clinical usage of the 31-GEP test by dermatologists.

Methods: Data from 589 unique dermatologists were collected during 2 virtual, nation-wide dermatology conferences via an 18-question survey on practice demographics and their clinical use and opinion of the 31-GEP test.

Results: Participants reported that integrating the 31-GEP test may benefit patients by increasing knowledge and understanding (72.5%), personalizing treatment options (58.8%), and easing uncertainty about the future (59.7%). Benefits of using the 31-GEP test included identifying true negative patients in high-risk populations (65.6%) as well as true positives in low-risk populations (70.6%). A majority of participants also noted that if a patient received a 31-GEP Class 2B result, they would escalate subsequent management even if the lesions were classified as T1 (61.4%) or AJCC8 Stage I (59.0%). 84.9% of participants were somewhat to very likely to use 31-GEP testing for patient management or recommend this test to a colleague.

Limitations: Potential respondent-selection and recall bias.

Conclusion: Dermatologists are increasingly integrating the 31-GEP test into their melanoma clinical management decisions. As the 31-GEP test becomes more prevalent in practice, patients may benefit from decreased anxiety and uncertainty from enhanced prognosis, decreased need for unwarranted procedures such as sentinel lymph node biopsy and optimized allocation of healthcare resources.
INTRODUCTION

The 31-gene expression profile test (31-GEP) (DecisionDx-Melanoma, Castle Biosciences, Inc., Friendswood, TX) analyses tissue collected from the initial diagnostic biopsy of a melanoma with an array of 31 genetic markers to assess prognosis. Prior studies have validated its ability to determine the risk of local/distant recurrence and sentinel lymph node positivity to assist in clinical decision-making. The 31-GEP test is reimbursable under Medicare, certified by the Clinical Laboratory Improvement Amendments (CLIA), and was ordered over 16,000 times during 2019. Given the increasingly widespread use of 31-GEP, the purpose of this study was to assess the professional understanding, opinions, and clinical usage of the 31-GEP test by dermatologists.

METHODS

The survey was available electronically via a website link during 2 national Dermatology conferences from October 29, 2020 to November 1, 2020 and January 16-24, 2021. Participants were asked to complete an 18 question survey regarding practice demographics, factors considered prior to ordering 31-GEP, their integration of 31-GEP results into clinical management, and their opinions on the usefulness of the test. IRB approval was obtained. Participants were compensated for their participation. Any duplicates were removed prior to data analysis.

RESULTS

After removing non-US respondents, 589 participants were eligible for the final analysis. Over 65% of the participants were practicing Dermatologists in a private practice setting with at least 11 years of independent practice experience. A majority of participants noted diagnosing <50 new melanomas in 2019 and ordering <20 31-GEP tests over a 12 month period.

Table 1. Participant Demographics. A majority of participants were practicing Dermatologists in a private practice setting with at least 11 years of independent practice experience. A majority of participants noted diagnosing <50 new melanomas in 2019 and ordering <20 31-GEP tests over a 12 month period.

| Demographics (n = 458) | % (n) |
|-----------------------|-------|
| Primary Specialty     |       |
| Dermatologist         | 89.5 (527) |
| Mohs Surgeon          | 9.2 (54) |
| Dermatopathologist    | 1.4 (8) |
| Years of Training     |       |
| Resident              | 20.5 (121) |
| 1-10 years            | 31.2 (184) |
| 11-20 years           | 19.4 (114) |
| 21-30 years           | 16.0 (94) |
| >30 years             | 12.9 (76) |
| Practice Type         |       |
| Private Practice      | 65.2 (384) |
| Academic              | 24.1 (142) |
| Multispecialty Group  | 7.1 (42) |
| Dermatology Group     | 1.4 (8) |
| Government            | 1.0 (6) |
| Other‡                | 1.0 (6) |
| How many newly diagnosed melanoma patients did you see in 2019? |       |
| <20                   | 47.5 (280) |
| 20-50                 | 41.1 (242) |
| 51-100                | 8.7 (51) |
| 101-200               | 1.9 (11) |
| >200                  | 0.8 (5) |
| In the past 12 months, how many times have you ordered the Castle 31-GEP test? |       |
| 0                     | 54.8 (323) |
| 1-20                  | 42.6 (251) |
| 21-50                 | 2.2 (13) |
| 51-100                | 0.3 (2) |

‡Other Practice Types: Unemployed (1), Volunteer (1), Locum Tenens (1), Retired (3)
melanomas in 2019 with 42.6% ordering between 1 and 20 31-GEP tests within the past 12 months.

A majority of participants reported that integrating the 31-GEP test may benefit patients by increasing knowledge and understanding (69.9%), personalizing treatment options (57.9%), and easing uncertainty about the future (58.6%) (Table 2). Even for patients with the lowest risk of recurrence (i.e. Class 1A), 65.9% of participants reported potential benefits for ameliorating patients’ anxiety and 45.8% reported increasing confidence in their management. Of the participants that offer the 31-GEP test to patients, 33.3% reported patients expressed no concerns with the test. If concerns were noted, the most common was the potential cost (30.9%).

Study participants reported that benefits of using the 31-GEP test included identifying true negative patients in high-risk populations (65.9%) as well as true positives in low-risk populations (70.1%). Additional benefits included using test results to determine referrals/follow-up frequency (36.3%) and informing discussion regarding potential sentinel lymph node biopsy (SLNBx) (36.0%). A majority reported Breslow thickness \( \geq 0.8 \text{mm} \) (68.6%) and patient age/sex/history (55.7%) were factored into their decision to order the test. A majority of participants also noted that if a patient received a 31-GEP Class 2B result (which has previously been found to carry increased risk for recurrence within 5 years\(^1\)), they would escalate subsequent management even if the lesions were classified as T1 (61.0%) or AJCC8 Stage I (58.7%).

Respondents believed potential false positive Class 2B results (i.e. patients at high risk of recurrence within 5 years that do not develop recurrence/metastasis) may be due to prompt/early intervention (71.3%), surgical excision prior to metastatic event (66.0%), or host immune response (71.5%) with a minority (31.2%) believing the result was an intrinsic error with the 31-GEP test. Going forward, 84.9% of participants were somewhat to very likely to use 31-GEP testing for patient management or recommend this test to a colleague and 66.0% would recommend a friend or family member receive the test as part of their care.

**DISCUSSION**

Our findings suggest that a majority of Dermatologists not only positively view 31-GEP testing, but are also incorporating it into management of their melanoma patients. Participants noted that having 31-GEP Class results had psychosocial benefits by aiding the physician-patient counseling, reducing anxiety and increasing confidence in the care plan. Given the test is reimbursable under Medicare, this may also ameliorate some patient concerns regarding the potential cost of the test.

From a clinical perspective, the way the studied Dermatologists report using 31-GEP testing largely follows published appropriate-use criteria for the 31-GEP test.\(^6\) Prior studies have determined the usage of the 31-GEP test with the strongest support in the literature was in informing discussions regarding the need for SLNBx (A-Strength SORT recommendation\(^7\)) with additional recommendation for facilitating management decisions of T1 and T2 melanomas and length of follow-up,\(^6\) which is consistent with our results. Participants also reported confidence in the test with a minority
Table 2. Participant Responses to Survey Questions.

| Survey Question                                                                 | % (95% CI)                                   |
|--------------------------------------------------------------------------------|----------------------------------------------|
| **What benefits do you think your patients gain from the Castle 31-GEP test results? (Select all that apply)** |                                              |
| Increased knowledge and understanding                                          | 69.9 (66.2-73.7)                             |
| Relief from uncertainty about future                                           | 58.6 (54.6 – 62.6)                          |
| More personalized treatment options                                            | 57.9 (53.9 – 61.9)                          |
| Information relevant to life planning                                         | 43.6 (39.6 – 47.6)                          |
| None                                                                          | 6.6 (4.6 – 8.6)                              |

**Most T1a patients (89.3%) will receive a low-risk GEP score. Do you think there's value in a T1a patient receiving a low-risk Class 1A result? (Select all that apply)**

|                                                                                  |                                              |
|                                                                                  |                                              |
| Yes, it relieves uncertainty for patients.                                      | 65.9 (62.0 – 69.7)                          |
| Yes, it makes me more confident in my treatment plan.                           | 45.8 (41.8 – 49.9)                          |
| Yes, other.                                                                    | 5.8 (3.9 – 7.7)                              |
| No, there is no value.                                                          | 16.0 (13.0 – 18.9)                          |

**Do patients ever express any concerns about having the Castle 31-GEP test performed or receiving the results of the test? (Select all that apply)**

|                                                                                  |                                              |
|                                                                                  |                                              |
| No                                                                              | 33.3 (29.5 – 37.1)                          |
| Yes-Concerns about the accuracy of the test                                     | 11.4 (8.8 – 13.9)                           |
| Yes-Concerns about the cost of test                                             | 30.9 (27.2 – 34.6)                          |
| Yes-Concerns about the risks of test                                            | 2.9 (1.5 – 4.2)                              |
| NA- I don't offer the test to my patients                                      | 34.5 (30.6 – 38.3)                          |

**For prognostic testing, which of the following provides a benefit for patient care? (Select all that apply)**

|                                                                                  |                                              |
|                                                                                  |                                              |
| Identifying a true negative in a high-risk population                           | 65.9 (62.0 – 69.7)                          |
| Identifying a true negative in a low-risk population                            | 33.6 (29.8 – 37.4)                          |
| Identifying a true positive in a high-risk population                           | 54.2 (50.1 – 58.2)                          |
| Identifying a true positive in a low-risk population                            | 70.1 (66.4 – 73.8)                          |
| None of the above                                                              | 2.2 (1.0 – 3.4)                              |

**How do you use Castle 31-GEP information? (select all that apply)**

|                                                                                  |                                              |
|                                                                                  |                                              |
| As part of my decisions for follow-up schedules and referrals                   | 36.3 (32.4 – 40.2)                          |
| As part of my decision to recommend or not recommend a patient having an SLNB | 36.0 (32.1 – 39.9)                          |
| To inform surveillance imaging                                                  | 22.1 (18.7 – 25.4)                          |
| To inform treatment decisions                                                   | 24.8 (21.3 – 28.3)                          |
| I don't use the Castle 31-GEP                                                   | 45.0 (41.0 – 49.0)                          |

**Which of the following factors would make you MORE likely to order the 31-GEP? (Select all that apply.)**

|                                                                                  |                                              |
|                                                                                  |                                              |
| Breslow thickness ≥ 0.8mm                                                        | 68.6 (64.8 – 72.3)                          |
| Presence of ulceration                                                          | 44.7 (40.6 – 48.7)                          |
| Negative sentinel lymph node biopsy                                             | 28.0 (24.4 – 31.6)                          |
| Mitotic rate ≥2/mm2                                                             | 45.8 (41.8 – 49.9)                          |
Which of the following factors do you also take into account when deciding to order the 31-GEP? (Select all that apply)

| Factor                             | Percentage (95% CI) |
|------------------------------------|---------------------|
| Patient Age/Sex/Clinical History   | 55.7 (51.7 – 59.7)  |
| Histological subtype              | 44.1 (40.1 – 48.2)  |
| Location of tumor                 | 34.3 (30.5 – 38.1)  |
| Clark level                        | 37.7 (33.8 – 41.6)  |
| None of the above                  | 26.5 (22.9 – 30.0)  |

T1 patients with a Class 1A (lowest risk) Castle 31-GEP result have a five-year recurrence free survival rate (RFS) of 96.8%, compared to T1 patients with a Class 2B (highest risk) result who have an RFS of 64.6%. Would receiving a Class 2B result for a T1 patient change your treatment plan?

| Response   | Percentage (95% CI) |
|------------|---------------------|
| Yes        | 61.0 (57.0 – 64.9)  |
| No         | 5.8 (3.9 – 7.7)     |
| I’m not sure| 33.3 (29.5 – 37.1)  |

Stage I patients with a Class 1A (lowest risk) Castle 31-GEP result have a five-year recurrence free survival rate (RFS) of 97.6%, compared to Stage I patients with a Class 2B (highest risk) result who have an RFS of 76.1%. Would receiving a Class 2B result for a Stage I patient change your treatment plan?

| Response   | Percentage (95% CI) |
|------------|---------------------|
| Yes        | 58.7 (54.8 – 62.7)  |
| No         | 6.1 (4.2 – 8.0)     |
| I’m not sure| 35.1 (31.3 – 39.0)  |

A recently published meta-analysis of the performance of the 31-GEP (Greenhaw et al., JAAD, 2020) demonstrates that patients with a Class 2B result are 3 times more likely to have a metastatic event compared to patients with a Class 1A result. However, not all Class 2B patients will have a recurrence or metastatic event (false positive result). In your opinion, which of the following factors could contribute to the receipt of a high-risk GEP result for a tumor that does not subsequently develop a recurrence or metastasis? (Select all that apply.)

| Factor                                    | Percentage (95% CI) |
|-------------------------------------------|---------------------|
| Surgical excision completed before metastasis of the cancer | 66.6 (62.7 – 70.4)  |
| Host immune system                        | 71.5 (67.8 – 75.1)  |
| Early intervention                         | 71.3 (67.7 – 75.0)  |
| Incorrect GEP result                       | 31.2 (27.5 – 35.0)  |
| Other (please specify)†                    | 1.9† (0.8 – 3.0)    |

If a close friend or family member were diagnosed with cutaneous melanoma, would you recommend that they get additional prognostic testing (such as gene expression profiling or GEP) to aid in their decision making and care?

| Response   | Percentage (95% CI) |
|------------|---------------------|
| Yes        | 66.0 (62.2 – 69.9)  |
| No         | 5.6 (3.7 – 7.5)     |
| I’m not sure| 28.4 (24.7 – 32.0)  |
How likely are you to use the Castle 31-GEP test for the care of your patients or to recommend the use of the test to a colleague?

| Likelihood          | Likelihood Score |
|---------------------|------------------|
| Very unlikely       | 4.4 (2.8 – 6.1)  |
| Not likely          | 13.8 (11.0 – 16.5) |
| Somewhat likely     | 47.7 (43.7 – 51.7) |
| Very likely         | 34.1 (30.3 – 38.0) |

†Insufficient follow-up time (1), possible sampling error from tissue biopsy (1), “something else” currently not understood (1), imperfect predictive value of gene profile (1)

attributing potential false-positives to intrinsic test errors and nearly 90% positively viewing, using, or recommending the test.

Limitations of this study include potential respondent-selection bias and the retrospective nature of the study. However, the method of questionnaire delivery (i.e. during a nation-wide virtual conference) potentially minimized regional bias and the studied sample population has a relatively uniform distribution of practice experience.

CONCLUSION

Dermatologists are increasingly integrating the 31-GEP test into their melanoma clinical management decisions. As the 31-GEP test becomes increasingly prevalent in practice, patients may benefit from decreased anxiety and uncertainty from enhanced prognosis, decreased need for potentially unnecessary procedures such as SLNBx and optimized allocation of healthcare resources. Future studies will be needed to determine the impact that the 31-GEP test will have on Dermatology practices and patient outcomes when fully integrated into current melanoma clinical management algorithms.

Conflict of Interest Disclosures: JWM, GHL, RS, AG have no relevant disclosures or conflicts of interest. ASF and RRW serve as consultants for Castle Bioscience, Inc. DSR serves as a consultant, advisory board member, and speaker for Castle Biosciences, Inc.

Funding: This study was funded in part by an unrestricted educational grant from Castle Biosciences, Inc.

Skin Cancer Prevention Working Group: The Skin Cancer Prevention Working Group is a multi-center collaboration of experts dedicated to the prevention of skin cancer. The Working Group consists of clinical and research specialists that have spent years investigating and understanding the diagnosis and management of melanoma and non-melanoma skin cancer.

The mission of the Working Group is to cultivate and analyze evidence-based research to better understand skin cancer pathophysiology, treatment, and prevention in order to be leaders in skin health education.

Corresponding Author:
Justin W. Marson, MD
35 E 35th St. #208
New York NY, 10016
Email: justin.w.marson@gmail.com

References:
1. Vetto JT, Hsueh EC, Gastman BR, et al. Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling. Future Oncol. 2019;15(11):1207-1217. https://www.futuremedicine.com/doi/10.2217/fon-2018-0912
2. Berman, B., Ceilley, R., Cockerell, C., Ferris, L., High, W. A., Lebwohl, M., Nestor, M. S., Rosen, T., Litchman, G. H., Prado, G., Svoboda, R. M., & Rigel, D. S. (2019). Appropriate Use Criteria for the Integration of Diagnostic and Prognostic Gene Expression Profile Assays into the Management of Cutaneous Malignant Melanoma: An Expert Panel Consensus-Based Modified Delphi Process Assessment. SKIN The Journal
3. Marks, E., Caruso, H. G., Kurley, S. J., Ibad, S., Plasseraud, K. M., Monzon, F. A., & Cockerell, C. J. (2019). Establishing an evidence-based decision point for clinical use of the 31-gene expression profile test in cutaneous melanoma. SKIN The Journal of Cutaneous Medicine, 3(4), 239-249. https://doi.org/10.25251/skin.3.4.2

4. Rigel DS, Ceilley RI, Litchman GH, Cockerell CJ. Gene expression profile testing in skin cancer prognosis: the data is clear – it's time to get on board. SKIN The Journal of Cutaneous Medicine. 2020;4 (4):304-308. https://jofskin.org/index.php/skin/article/view/937

5. Greenhaw BN, Covington KR, Kurley SJ, Yeniay Y, Cao NA, Plasseraud KM, Cook RW, Hsueh EC, Gastman BR, Wei ML. Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients. J Am Acad Dermatol. 2020 Sep;83(3):745-753. doi: 10.1016/j.jaad.2020.03.053. Epub 2020 Mar 27. PMID: 32229276.

6. Berman, B., Ceilley, R., Cockerell, C., Ferris, L., High, W. A., Lebwohl, M., Nestor, M. S., Rosen, T., Litchman, G. H., Prado, G., Svoboda, R. M., & Rigel, D. S. (2019). Appropriate Use Criteria for the Integration of Diagnostic and Prognostic Gene Expression Profile Assays into the Management of Cutaneous Malignant Melanoma: An Expert Panel Consensus-Based Modified Delphi Process Assessment. SKIN The Journal of Cutaneous Medicine, 3(5), 291-306. https://doi.org/10.25251/skin.3.5.1

7. Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. American family physician 2004;69:548-56.